Axsome Therapeutics (AXSM) had the best year in 2019 by a large-cap US stock in 2019, returning 3,578.3%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Axsome Therapeutics (AXSM) | 2019 | 3,578.29% |
Arrowhead Pharmaceuticals (ARWR) | 2019 | 421.63% |
Roku (ROKU) | 2019 | 349.03% |
Sea (SE) | 2019 | 261.69% |
Carvana (CVNA) | 2019 | 190.56% |
Lattice Semiconductor (LSCC) | 2019 | 179.01% |
Krystal Biotech (KRYS) | 2019 | 171.2% |
Advanced Micro Devices (AMD) | 2019 | 154.64% |
Natera (NTRA) | 2019 | 146.81% |
Tenet Healthcare (THC) | 2019 | 125.43% |
Ascendis Pharma A-S (ASND) | 2019 | 125% |
Teradyne (TER) | 2019 | 124.96% |
Lam Research (LRCX) | 2019 | 123.79% |
Insulet (PODD) | 2019 | 120.19% |
Carlyle (CG) | 2019 | 119.12% |
Ares Management (ARES) | 2019 | 113.99% |
Somnigroup International (SGI) | 2019 | 113.65% |
Apollo Global Management LLC Class A (APO) | 2019 | 111.2% |
Guardant Health (GH) | 2019 | 110.28% |
KLA (KLAC) | 2019 | 108.55% |
Generac (GNRC) | 2019 | 106.38% |
BioNTech SE (BNTX) | 2019 | 105.33% |
Leonardo DRS, Inc Common Stock (DRS) | 2019 | 105.14% |
Fair Isaac (FICO) | 2019 | 103.45% |
Target (TGT) | 2019 | 103.34% |
Large-cap stocks are treated as having a market cap of $10B+.